In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Opens Up to Europe

Executive Summary

Despite a strong trend among Big Pharma towards in-licensing over the last decade, Merck & Co. hasn't been particularly willing to embrace research ideas outside its own labs. But that's changing. Merck's new European in-licensing initiative proves that the Big Pharma recognizes, and hopes to access, the wealth of science and potential deals beyond US borders.

You may also be interested in...



Merck's Deal Focus

Merck & Co. Inc.'s recovery drive involves changing every aspect of its business, and doing so urgently. That urgency applies to partnering, too: In March 2006, the giant announced three new deals, one with NicOx on a series of anti-hypertension compounds, one with Neuromed in pain and the third with Paratek Pharmaceuticals Inc. for a Phase I antibiotic. They mark a shift at Merck towards more clinical stage dealmaking.

The Winners Post-Vioxx: Merck's Product-Focused Biotechs

Vioxx's withdrawal late in September just made partnering success even more critical to Merck & Co. With a $2.55 billion gap in revenues from Vioxx and having lost two Phase III development products late in 2003, the company now leans more heavily still on external R&D success. That's good news for Merck's partners--particularly those with products.

Merck/DeCode: Just Another Pharmacogenomics Deal?

Merck's deal with deCode provides valuable endorsement of the Icelandic firm's clinical development expertise, and reinforces the Big Pharma's partnering drive. But although interesting scientifically-the partners claim the deal is different in scope and nature to most pharmacogenomics projects-this alliance is unlikely, in the near term at least, to improve Merck's chances of late-stage success.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel